Genmab A/S · OMXCOP:GMAB
Genmab A/S — Corporate Update (September 2010)
29 slides from Genmab A/S's corporate update, Sep 14, 2010
Slide 1: Strategy Update
Strategy Update September 14, 2010
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, inclu
Slide 3: Agenda
Agenda Life science landscape Accomplishments Our Go Forward strategy What’s different Antibody technology innovation A new strategic relationship Envisioned future Q&A 3
Slide 4: Big Pharma Needs Biotech
Big Pharma Needs Biotech Biotechnology key to fill innovation gap 1/3 of new drugs in development from Biotech Next generation technologies Biologics fuel Big Pharma drug development Antibodies: biggest portion of sales growth, at fastest rate# Big Pharma networking with Biotech Global credit crisis
Slide 5: Major Accomplishments
Major Accomplishments Demonstrated ability from lab to market Arzerra to market in < 8 years World class research & discovery engine String of preclinical products Next generation technologies Efficient discovery & development human antibodies IND generating machine 11 INDs in 11 years, 7 still in d
Slide 6: Better Antibodies By Design
Strategy Focus on core competence Turn science into medicine - into real value Build a profitable & successful Biotech Better Antibodies By Design 6
Slide 7: Strategy – Focus on Core Competence
Strategy – Focus on Core Competence World class antibody discovery & development Extract value from validated technology Create & exploit innovation, IP & know-how Lead in next generation technologies Industrial Strength Research Engine 7
Slide 8: Strategy – Turn Science into Medicine
Strategy – Turn Science into Medicine Create real value Skilled team with ability to select right antibody for right purpose Streamlined, high throughput process Unsurpassed antibody validation Carefully invest in a stepwise fashion based on proof of concept milestones Science, Medicine & Business R
Slide 9: Strategy – Build a Profitable & Successful Biotech
Strategy – Build a Profitable & Successful Biotech Flexible, lean and efficient operating model Selectively invest in products that will add most value Cap failures early Make better spending decisions Maximize value through partnerships Better Antibodies By Design 9
Slide 10: So What Will Be Different?
So What Will Be Different? Focus Discipline Balance Execution 10
Slide 11: So What Will Be Different?
So What Will Be Different? Focus on Dominant priorities Sustainability Disciplined approach Efficient, productive & lean Core skills in-house, outsourcing where skills are not unique Balance science with business acumen Selective investments Cap failures early Drive value through partnerships 11
Slide 12: So What Will Be Different?
So What Will Be Different? Focus Discipline Balance Execution 12
Slide 13: Focus on Dominant Priorities
Focus on Dominant Priorities Arzerra Maximize value together with GSK Zalutumumab Establish optimal regulatory path, set up partnership Promote sale of manufacturing facility Daratumumab Clinical proof of concept 13
Slide 14: Focus on Dominant Priorities
Focus on Dominant Priorities Extract value from R&D engine and pipeline New strategic partnerships Optimize ways to advance next generation technologies Manage and control cash burn 14
Slide 15: So What Will Be Different?
So What Will Be Different? Focus Discipline Balance Execution 15
Slide 16: Disciplined Approach - Lean Expense Base
Disciplined Approach - Lean Expense Base 1800 DKK 1.6 Bil. DKK 0.9 Bil. 1600 201 1400 380 1200 DKK Millions 1000 60 800 570 210 600 390 400 464 200 250 0 2008 actual 2010 estimate Staffing Costs Top 3 Products All other MN facility 16
Slide 17: Disciplined Approach – Core Skills In-house
Disciplined Approach – Core Skills In-house Employees 700 643 600 500 417 400 300 217 159 175 200 100 51 33 25 0 R&D G&A Minnesota Total September 2008 June 2010 17
Slide 18: Disciplined Approach – Smart Trials
Disciplined Approach – Smart Trials “Rapidity does not always mean progress, and hurry is akin to waste. The old fable of the hare and the tortoise is just as good now, and just as true, as when it was first written.” Charles A. Stoddard Smart trial design, participation involving: All internal disc
Slide 19: So What Will Be Different?
So What Will Be Different? Focus Discipline Balance Execution 19
Slide 20: Balance Science with Business Acumen
Balance Science with Business Acumen Selective Investments Selectively invest in products that will likely add most value Scale up product investment in a stepwise fashion, based on successive proof of concept milestones Multi-disciplined Portfolio Board Gate 0 Gate 1 Gate 2 Gate 3 Gate 4 Gate 5 Tar
Slide 21: Balance Science with Business Acumen: Drive Value Through Partnerships
Balance Science with Business Acumen Drive Value Through Partnerships Antibody-drug conjugates represent key next generation cancer therapeutics New ADC collaboration with Seattle Genetics Genmab gains access to new platform Seattle Genetics gains access to a pipeline product Seattle Genetics option
Slide 22: Enhancing Antibody Effectiveness
Enhancing Antibody Effectiveness Novelty: Low High Development time: Short Long 22
Slide 23: Antibody-Drug Conjugates
Antibody-Drug Conjugates Principle Antibody-Drug Conjugate (ADC) Medicine with a toxic part which is selectively released inside the tumor Combine best properties of Antibodies: specificity Chemotherapy: tumor toxicity Increased drug delivery to tumor Decreased normal tissue exposure 23
Slide 24: Broad Pipeline ≥7 INDs in 5 Years
Broad Pipeline ≥7 INDs in 5 Years Product Category 1999 - 2010 2011 2012 2013 2014 Various Various 11 INDs Filed HuMax-cMet Best-in-Class IND HuMax-TF First-in-Class [ADC] IND HuMax-Her2 Best-in-Class IND First-in-Class 2 INDs 2 INDs Future Pool Candidates 2 INDs 24
Slide 25: HuMax-TF
HuMax-TF First-in-Class ADC TF as cancer target Involved in key cancer mechanisms Normal pancreas Inhibition apoptosis, promotion of angiogenesis & metastasis Highly expressed many solid tumors incl. Pancreatic & colorectal cancers Lead candidates available Pancreatic tumor Inhibit FVIIa induced sig
Slide 26: Enhancing Antibody Effectiveness
Enhancing Antibody Effectiveness Novelty: Low High Development time: Short Long 26
Slide 27: Envisioned Future – A Premier Biotech
Envisioned Future – A Premier Biotech 2020 5 marketed products, 10 key partners, next generation a reality, no capital constraints 2010 Arzerra on market, broad pipeline, 2 key partnerships, burning cash 2000 Access to technology, small beginnings Become the World-Leading Networked Antibody Company
Slide 28: To Create & Develop Human Antibodies to Improve Patients' Lives
To Create & Develop Human Antibodies to Improve Patients’ Lives 28
Slide 29: Q&A
Q&A